TY  - JOUR

T1  - Abstract S4-3: Ten-Year Follow-Up Analysis of the BICRG 001 Trial Confirms Superior DFS and OS Benefit of Adjuvant TAC (Docetaxel, Doxorubicin, Cyclophosphamide) over FAC (fluorouracil, Doxorubicin, Cyclophosphamide) in Women with Operable Node-Positive Breast Cancer

JO  - General Session Abstracts

PY  - 2010/12/15

AU  - Martin M

AU  - Mackey J

AU  - Pienkowski T

AU  - Rolski J

AU  - Guastalla J-P

AU  - Sami A

AU  - Glaspy J

AU  - Juhos E

AU  - Wardley A

AU  - Fornander T

AU  - Hainsworth J et al

ED  - 

DO  - DOI: 10.1158/0008-5472.sabcs10-s4-3

PB  - American Association for Cancer Research

Y2  - 2025/10/10

ER  -